Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / articles / VYNE - Positive Momentum For VYNE Therapeutics' Psoriasis Rheumatoid Arthritis Candidate - Analyst Expresses Encouragement | Benzinga

VYNE - Positive Momentum For VYNE Therapeutics' Psoriasis Rheumatoid Arthritis Candidate - Analyst Expresses Encouragement | Benzinga

VYNE Therapeutics Inc Com

Earlier today, VYNE Therapeutics Inc (NASDAQ: VYNE) released new preclinical data showing the positive effect of its VYN202 in preclinical models of psoriasis and rheumatoid arthritis.

VYNE expects to submit its IND for VYN202 by year-end 2023 and commence a first-in-human Phase 1a single ascending dose/multiple ascending dose trial in the first quarter of 2024. 

If successful, VYNE anticipates commencing Phase 1b trials in moderate-to-severe plaque psoriasis and moderate-to-severe adult-onset rheumatoid arthritis in the second half of 2024.

VYNE Therapeutics also announced private placement financing Full story available on Benzinga.com
Stock Information
Company Name: VYNE Therapeutics Inc Com
Stock Symbol: VYNE
Market: NASDAQ
Website: vynetherapeutics.com
Menu
VYNE VYNE Quote VYNE Short VYNE News VYNE Articles VYNE Message Board
Get VYNE Alerts

News, Short Squeeze, Breakout and More Instantly...